Radiolabeling of neurotensin agonist and antagonist with 177Lu: bioafinity of 177Lu-DOTA-NT and 177Lu-DOTA-SR48692 to neurotensin receptors

被引：1
|
作者：
Lungu, Valeria [1 ]
机构：
[1] Horia Hulbei Natl Inst Phys & Nucl Engn, Magurele, Ilfov County, Romania
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2010年 / 37卷 / 06期
关键词：
D O I：
10.1016/j.nucmedbio.2010.04.142
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：691 / 691
页数：1
相关论文
共 50 条
  • [1] Therapeutic Efficacy Evaluation of 177Lu-DOTA-NT and 177Lu-DOTA-SR48692 in Murine RS-1 Hepatoma
    Panait, Marieta Elena
    Chiper, Diana
    Negoita, Valentina
    Lungu, Valeria
    Gruia, Maria Iuliana
    INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2013, 19 (04) : 345 - 356
  • [2] Therapeutic Efficacy Evaluation of 177Lu-DOTA-NT and 177Lu-DOTA-SR48692 in Murine RS-1 Hepatoma
    Marieta Elena Panait
    Diana Chiper
    Valentina Negoita
    Valeria Lungu
    Maria Iuliana Gruia
    International Journal of Peptide Research and Therapeutics, 2013, 19 : 345 - 356
  • [3] RADIOLABELLING OF NEUROTENSIN AGONIST AND ANTAGONIST WITH 177Lu
    Lungu, V.
    Chiper, D.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2009, 52 : S484 - S484
  • [4] RADIOLABELLING OF NEUROTENSIN AGONIST AND ANTAGONIST WITH 177LU
    Lungu, Valeria
    Chiper, Diana
    Matei, Lidia
    Barna, Catalina
    Gruia, Iuliana
    Tuta, Catalin
    Postolache, Cristian
    Cimpeanu, Catalina
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2010, 53 (5-6): : 466 - 468
  • [5] Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
    Heribert Hänscheid
    Philipp E. Hartrampf
    Andreas Schirbel
    Andreas K. Buck
    Constantin Lapa
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 2566 - 2572
  • [6] Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
    Haenscheid, Heribert
    Hartrampf, Philipp E.
    Schirbel, Andreas
    Buck, Andreas K.
    Lapa, Constantin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (08) : 2566 - 2572
  • [7] Microfluidic synthesis of [177Lu]Lu-DOTA-TATE
    Liu, Zheng
    Schaap, Kevin
    Rohde, Martin
    Oehlke, Elisabeth
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 : S462 - S462
  • [8] Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [177Lu]Lu-OPS201 Compared to the Agonist [177Lu]Lu-DOTA-TATE
    Mansi, Rosalba
    Plas, Pascale
    Vauquelin, Georges
    Fani, Melpomeni
    PHARMACEUTICALS, 2021, 14 (12)
  • [9] Re-treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE of patients with progressive neuroendocrine neoplasm
    Durma, Adam Daniel
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Mroz, Adrianna
    Kapusta, Waldemar
    Dmochowska, Beata
    Kaminski, Grzegorz
    NUCLEAR MEDICINE REVIEW, 2023, 26 : 143 - 152
  • [10] Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
    Wehrmann, Christiane
    Senftleben, Stefan
    Zachert, Carolin
    Mueller, Dirk
    Baum, Richard P.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (03) : 406 - 416
12345